Historical Valuation
ABVC Biopharma Inc (ABVC) is now in the Undervalued zone, suggesting that its current forward PS ratio of 12.37 is considered Undervalued compared with the five-year average of -4.74. The fair price of ABVC Biopharma Inc (ABVC) is between 53.84 to 55.71 according to relative valuation methord. Compared to the current price of 2.18 USD , ABVC Biopharma Inc is Undervalued By 95.95%.
Relative Value
Fair Zone
53.84-55.71
Current Price：2.18
95.95%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
ABVC Biopharma Inc (ABVC) has a current Price-to-Book (P/B) ratio of 4.26. Compared to its 3-year average P/B ratio of 1.83 , the current P/B ratio is approximately 132.70% higher. Relative to its 5-year average P/B ratio of 9.66, the current P/B ratio is about -55.89% higher. ABVC Biopharma Inc (ABVC) has a Forward Free Cash Flow (FCF) yield of approximately -4.40%. Compared to its 3-year average FCF yield of -31.13%, the current FCF yield is approximately -85.88% lower. Relative to its 5-year average FCF yield of -25.57% , the current FCF yield is about -82.81% lower.
P/B
Median3y
1.83
Median5y
9.66
FCF Yield
Median3y
-31.13
Median5y
-25.57
Competitors Valuation Multiple
AI Analysis for ABVC
The average P/S ratio for ABVC competitors is 1320.13, providing a benchmark for relative valuation. ABVC Biopharma Inc Corp (ABVC.O) exhibits a P/S ratio of 12.37, which is -99.06% above the industry average. Given its robust revenue growth of 104.47%, this premium appears sustainable.
Performance Decomposition
AI Analysis for ABVC
1Y
3Y
5Y
Market capitalization of ABVC increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ABVC in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ABVC currently overvalued or undervalued?
ABVC Biopharma Inc (ABVC) is now in the Undervalued zone, suggesting that its current forward PS ratio of 12.37 is considered Undervalued compared with the five-year average of -4.74. The fair price of ABVC Biopharma Inc (ABVC) is between 53.84 to 55.71 according to relative valuation methord. Compared to the current price of 2.18 USD , ABVC Biopharma Inc is Undervalued By 95.95% .
What is ABVC Biopharma Inc (ABVC) fair value?
ABVC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of ABVC Biopharma Inc (ABVC) is between 53.84 to 55.71 according to relative valuation methord.
How does ABVC's valuation metrics compare to the industry average?
The average P/S ratio for ABVC's competitors is 1320.13, providing a benchmark for relative valuation. ABVC Biopharma Inc Corp (ABVC) exhibits a P/S ratio of 12.37, which is -99.06% above the industry average. Given its robust revenue growth of 104.47%, this premium appears sustainable.
What is the current P/B ratio for ABVC Biopharma Inc (ABVC) as of Jan 10 2026?
As of Jan 10 2026, ABVC Biopharma Inc (ABVC) has a P/B ratio of 4.26. This indicates that the market values ABVC at 4.26 times its book value.
What is the current FCF Yield for ABVC Biopharma Inc (ABVC) as of Jan 10 2026?
As of Jan 10 2026, ABVC Biopharma Inc (ABVC) has a FCF Yield of -4.40%. This means that for every dollar of ABVC Biopharma Inc’s market capitalization, the company generates -4.40 cents in free cash flow.
What is the current Forward P/E ratio for ABVC Biopharma Inc (ABVC) as of Jan 10 2026?
As of Jan 10 2026, ABVC Biopharma Inc (ABVC) has a Forward P/E ratio of -0.48. This means the market is willing to pay $-0.48 for every dollar of ABVC Biopharma Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for ABVC Biopharma Inc (ABVC) as of Jan 10 2026?
As of Jan 10 2026, ABVC Biopharma Inc (ABVC) has a Forward P/S ratio of 12.37. This means the market is valuing ABVC at $12.37 for every dollar of expected revenue over the next 12 months.